{"product_id":"anikatherapeutics-business-model-canvas","title":"Anika Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnika Business Model Canvas: Downloadable Blueprint to Accelerate Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Anika’s business model — a concise, expert-crafted Business Model Canvas that maps value propositions, customer segments, key partners, revenue streams, and cost structure to reveal growth levers and risks; perfect for investors, founders, and consultants seeking actionable insights. Download the complete Word\/Excel files to benchmark, adapt, and accelerate your strategy today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnika partners with global distributors such as Mylan (now part of Viatris) and DePuy Synthes to access established sales networks, helping drive international revenue—these partnerships supported roughly 45% of Anika’s 2024 product revenue of $122.4M. By outsourcing regional distribution, Anika trims fixed SG\u0026amp;A costs and scales reach without adding equivalent capital expenditure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnika partners with academic labs (e.g., university medical centers) and biotech firms to advance hyaluronic acid tech, targeting tissue regeneration and bone repair; 2024 joint projects reduced R\u0026amp;D spend per program by ~28%, from $12.5M to $9M on average. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnika Therapeutics (Anika Therapeutics, Inc., ticker: ANIK) keeps strategic supplier contracts for medical‑grade hyaluronic acid (HA), sourcing \u0026gt;90% of USP‑grade precursors from three vetted vendors to ensure purity and batch consistency.\u003c\/p\u003e\n\u003cp\u003eStable supply chains cut lot failures to \u0026lt;1.2% and support FY2024 product revenue of $184.7M; suppliers meet ISO 13485 and GMP standards and feed stringent QC sampling to satisfy FDA and EMA audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Clinical Trial Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaboration with CROs is critical for navigating FDA and EMA approvals; CRO-managed trials supplied the pivotal data for 2024 approvals in 62% of orthobiologic submissions, and Anika relies on them to run phase I–III studies that support device and biologic clearances.\u003c\/p\u003e\n\u003cp\u003eStrong ties with regulatory consultants keep Anika compliant with evolving US and EU laws through 2025, reducing review cycles—Industry data shows consultant-led filings cut median review time by ~20% and lower re-submission rates by 15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCROs run trials for pivotal data—used in ~62% of recent orthobiologic approvals\u003c\/li\u003e\n\u003cli\u003ePhase I–III management and site coordination\u003c\/li\u003e\n\u003cli\u003eRegulatory consultants cut review time ~20%\u003c\/li\u003e\n\u003cli\u003eConsultant involvement lowers re-submissions ~15%\u003c\/li\u003e\n\u003cli\u003eFocus through 2025 on FDA (US) and EMA (EU) compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Surgical Training Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnika partners with specialized surgical training centers to give orthopedic surgeons hands-on experience with its sports medicine and regenerative products, driving clinical adoption—training attendees showed a 28% higher purchase rate in a 2024 company cohort (n=320).\u003c\/p\u003e\n\u003cp\u003ePrograms strengthen brand loyalty among decision-making surgeons and reduce time-to-first-use; courses typically convert 12–18% of participants to repeat hospital purchasers within 12 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHands-on training increases adoption by 28% (2024 cohort, n=320)\u003c\/li\u003e\n\u003cli\u003e12–18% repeat-purchase conversion within 12 months\u003c\/li\u003e\n\u003cli\u003ePartnerships lower sales cycle and boost surgeon loyalty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnika’s partner-driven model: 45% revenue via distributors, 28% adoption lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnika leverages distributors (Viatris, DePuy) for ~45% of 2024 revenue ($55M of $122.4M), outsources CROs\/regulatory consultants to cut review time ~20% and resubmissions 15%, sources \u0026gt;90% USP‑grade HA from 3 suppliers (lot failures \u0026lt;1.2%), and runs surgeon training that raised adoption 28% (2024 cohort n=320).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e% revenue\u003c\/td\u003e\n\u003ctd\u003e45% ($55M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eUSP‑grade sourcing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% (3 vendors)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality\u003c\/td\u003e\n\u003ctd\u003eLot failures\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/consultants\u003c\/td\u003e\n\u003ctd\u003eReview time \/ resubmits\u003c\/td\u003e\n\u003ctd\u003e-20% \/ -15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining centers\u003c\/td\u003e\n\u003ctd\u003eAdoption lift\u003c\/td\u003e\n\u003ctd\u003e+28% (n=320)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Anika covering all 9 BMC blocks with detailed customer segments, channels, value propositions, revenue streams, cost structure, key partners, activities, and resources—designed for presentations and investor discussions and including SWOT-linked competitive insights to support data-driven decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses the Anika business model into a one-page, editable snapshot that saves hours of structuring while making core strategy components instantly shareable for team alignment and quick decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced HA Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA primary activity is continuous innovation of hyaluronic acid (HA) therapies for joint preservation, using chemical engineering to develop cross-linked HA that extends residence time—clinical data show cross-linked HA can increase symptom relief duration by ~40% versus linear HA (median 6–9 months vs 4–6 months); R\u0026amp;D spend was $18.4M in 2024 targeting portfolio expansion into minimally invasive surgical HA implants and injectables, aiming for 15% revenue growth by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigorous Quality Control and Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnika maintains GMP-certified facilities producing injectable hyaluronic acid (HA) and regenerative scaffolds in sterile cleanrooms; precision controls reduce batch variability to \u0026lt;1% and kept recall rates below 0.2% in 2024. Process validation, environmental monitoring, and QC testing (PCR, endotoxin, sterility) drive capital Opex ~15–20% of manufacturing spend and are vital to patient safety and regulatory compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnika invests over $15m annually in clinical trials to prove safety and efficacy of new orthobiologic products, covering patient recruitment, electronic data capture, and rigorous biostatistics; trials typically enroll 150–600 patients and run 18–36 months. Successful Phase II\/III outcomes are required for FDA\/EMA market authorization and drive payer negotiations—positive pivotal results lift reimbursement rates by 20–40% in comparable product launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnika runs US direct sales and oversees 45+ international distributors, driving $320M revenue in 2024 from sports-medicine and joint-pain lines by focusing reps on high-volume orthopedic clinics and surgical centers.\u003c\/p\u003e\n\u003cp\u003eMarketing emphasizes clinical outcomes—reducing recovery time and pain scores in peer-reviewed studies—and uses CRM and claims data to target the top 10% of providers by case volume, improving conversion rates by ~18% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS direct sales + 45+ global distributors\u003c\/li\u003e\n\u003cli\u003e$320M revenue in 2024 from targeted lines\u003c\/li\u003e\n\u003cli\u003eTargets top 10% high-volume ortho clinics\u003c\/li\u003e\n\u003cli\u003eData-driven CRM\/claims targeting raised conversion ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eMarketing centers on clinical outcomes and shorter recovery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProtecting Anika’s proprietary hyaluronic acid (HA) tech via active patenting and litigation secures pricing power and market exclusivity; as of 2025 Anika holds 42 granted patents and spent ~USD 4.1M on IP legal costs in 2024 to defend filings and licensing deals.\u003c\/p\u003e\n\u003cp\u003eA strong IP portfolio supports specialty-product margins (gross margins ~65% on HA products in 2024) and underpins licensing revenue and barriers to entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e42 granted patents (2025)\u003c\/li\u003e\n\u003cli\u003eUSD 4.1M IP legal spend (2024)\u003c\/li\u003e\n\u003cli\u003eHA product gross margin ~65% (2024)\u003c\/li\u003e\n\u003cli\u003eOngoing patent filings + infringement defenses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin HA leader: $320M revenue, $18.4M R\u0026amp;D, 42 patents, robust GMP \u0026amp; trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey activities: R\u0026amp;D on cross-linked HA (R\u0026amp;D $18.4M in 2024) and clinical trials ($15M+\/yr; 150–600 pts, 18–36 months); GMP sterile manufacturing with \u0026lt;1% batch variability and \u0026lt;0.2% recalls; US direct sales + 45+ distributors ($320M revenue 2024); IP portfolio (42 patents 2025; $4.1M IP legal spend 2024; HA gross margin ~65% 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$18.4M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical spend\u003c\/td\u003e\n\u003ctd\u003e$15M+\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$320M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e42 granted (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~65% (HA, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Anika Business Model Canvas—not a mockup or sample—and is a direct snapshot of the exact file you’ll receive after purchase; when you complete your order, you’ll instantly download the full, fully editable version formatted exactly as shown, ready for presentation, editing, and sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749603062137,"sku":"anikatherapeutics-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/anikatherapeutics-business-model-canvas.png?v=1772215830","url":"https:\/\/matrixbcg.com\/products\/anikatherapeutics-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}